Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to ...
Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging net product ...
Alpha Vision announced it will showcase its Physical AI Outdoor Security Platform at the Blueprint conference in Las Vegas. The platform uses autonomous AI agents and fully automated workflows to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback